Promising Drugs For Non-Hodgkin’s Lymphoma May Change European Market Dynamics

January 30th, 2008 | Category: Cancer

The European non-Hodgkin’s lymphoma (NHL) therapeutics market has been monopolised by MabThera for a number of years. Although cut chemotherapy is the major treatment for all forms of NHL, it is highly genericised with limited prospects for revenue growth. However, market

dynamics are poised to change in the near future due to the anticipated launch of many promising pipeline drugs currently in phase 3 of their development.

Original post by Women’s Health / Gynecology News From Medical News Today

Share and Enjoy: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Netvouz
  • DZone
  • ThisNext
  • MisterWong
  • Wists
  • BlinkList
  • Furl
  • IndianPad
  • Netscape
  • Reddit
  • Simpy
  • Spurl
  • StumbleUpon
  • Technorati
Related Articles
  • Studying Mutations In Non-Hodgkin Lymphoma Yields Clues For Potential New Therapies
  • New Study Shows Environmental Contaminants Increase Risk Of Non-Hodgkin Lymphoma, Canada
  • REVLIMID® Provides Responses For Patients With Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma, Preliminary Study Results
  • Patients With Non-Hodgkin’s Lymphoma Have Shown Improved Outlook In Last Decade
  • September Is Leukemia, Lymphoma And Myeloma Awareness Month

    • No comments yet. Be the first.

    Leave a reply

    You must be logged in to post a comment.